[Genomic expression tests in patients with breast cancer: MammaPrint®, Oncotype DX® and Prosigna®]

Gonzalez L, Bardach A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32015001153
Spanish
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage policy related aspects regarding the use of genomic expression tests in patients with breast cancer.
Authors' recomendations: The evidence found supporting the use of the genomic expression tests in patients with early breast cancer is of low methodological quality. It is based on the retrospective analysis of selected and heterogeneous samples from patients who are in general at early stages; they show that the test result would act as an independent prognostic factor, in some cases predictive of the potential benefit of administering chemotherapy on results such as mortality and recurrence risk. The lack of studies assessing the change in therapeutic decision after performing the test and its further clinical impact limit its recommendation. The main international societies mention the possibility of using them when the risk of recurrence assessment is uncertain, after analyzing traditional clinical and anatomopathological factors, specially recommending Oncotype DX®. MammaPrint® and Prosigna® are still considered at investigational stage.
Details
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Humans
  • Breast Neoplasms
  • Genomics
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.